ClinicalTrials.gov
public full text
Public Domain
Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty
Can risedronate given once weekly for 6 months prevent periprosthetic bone loss after uncemented total hip arthroplasty?
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women#883574
- Zoledronate Early to Hip Fracture Patients - Safe and Effective?#917077
- Can Perineal Post-Free Traction in Hip Arthroscopy Effectively Reduce Perineal Complications?#855099
- Risedronate in the Prevention of Osteoporosis in Postmenopausal Women#859384
- Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation#844032
Record · ID 1010700
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive